ONCORESPONSE
OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, to interrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive ... immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
ONCORESPONSE
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.oncoresponseinc.com
Total Employee:
11+
Status:
Active
Contact:
206-805-1600
Total Funding:
103.1 M USD
Technology used in webpage:
SPF Domain Not Resolving Euro Microsoft Exchange Online Office 365 Mail GoDaddy DNS GoDaddy Zoom Video Conferencing Zoom KnowBe4
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Board_member
2021-03-01
Board_member
2021-03-01
Board_member
2021-03-01
Board_member
Board_member
Board_member
Board_member
2016-01-01
Board_member
Current Employees Featured
Bob Lechleider Chief Medical Officer @ OncoResponse
Chief Medical Officer
2020-01-01
Clifford J. Stocks CEO @ OncoResponse
CEO
2015-10-01
Kamal D. Puri Chief Scientific Officer @ OncoResponse
Chief Scientific Officer
2018-01-01
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-11-07 | Paganini Biopharma | Paganini Biopharma acquired by OncoResponse | N/A |
Investors List
Bering Capital
Bering Capital investment in Series C - OncoResponse
ARCH Venture Partners
ARCH Venture Partners investment in Series C - OncoResponse
RiverVest
RiverVest investment in Series C - OncoResponse
Qatar Investment Authority
Qatar Investment Authority investment in Series C - OncoResponse
Canaan Partners
Canaan Partners investment in Series C - OncoResponse
Redmile Group
Redmile Group investment in Series C - OncoResponse
Yonjin Venture
Yonjin Venture investment in Series C - OncoResponse
3B Future Health Fund
3B Future Health Fund investment in Series C - OncoResponse
Magnetar Capital
Magnetar Capital investment in Series C - OncoResponse
Qatar Investment Authority
Qatar Investment Authority investment in Series B - OncoResponse
Official Site Inspections
http://www.oncoresponseinc.com
- Host name: 132.44.180.107.host.secureserver.net
- IP address: 107.180.44.132
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "OncoResponse"
OncoResponse - Crunchbase Company Profile & Funding
Contact Email info@oncoresponseinc.com Phone Number +1 206 805 1600 OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform …See details»
About OncoResponse - About - OncoResponse
609 Main St, Suite 4200 Houston, TX 77002 United States 1124 Columbia St, Suite 300 Seattle, WA 98104 United States. info@oncoresponse.com P: 206-805-1600 F: 206-805-1699See details»
Leadership Team - About - OncoResponse
Chris Russell, MBA Chief Financial Officer. Chris Russell provides financial and operational leadership at OncoResponse. He has over 30 years of experience as a growth company executive and entrepreneur, launching highly successful …See details»
OncoResponse Company Profile | Management and Employees …
OncoResponse Profile and History. OncoResponse, Inc., an immuno-oncology focused biotech company, in a broad strategic alliance with MD Anderson Cancer Center, uses a proprietary B …See details»
OncoResponse, Inc. Company Profile | Houston, TX | Competitors ...
OncoResponse, Inc. D&B Business Directory HOME / BUSINESS DIRECTORY / PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES / SCIENTIFIC RESEARCH …See details»
OncoResponse - Funding, Financials, Valuation & Investors
OncoResponse has a post-money valuation in the range of $100M to $500M as of May 18, 2023, according to PrivCo.Sign up for a free trial to view exact valuation and search companies with …See details»
OncoResponse Inc - Company Profile and News - Bloomberg …
Company profile page for OncoResponse Inc including stock price, company news, executives, board members, and contact informationSee details»
OncoResponse Inc. - Life-Sciences-Europe.com
Oct 10, 2016 OncoResponse, Inc., an immuno-oncology focused biotech company, in a broad strategic alliance with MD Anderson Cancer Center uses a proprietary B-cell technology …See details»
Oncoresponse, Inc. - Company Profile - Corporation Wiki
Oncoresponse, Inc. Overview. Oncoresponse, Inc. filed as a Foreign For-Profit Corporation in the State of Texas on Thursday, August 17, 2023 and is approximately two years old, as recorded …See details»
OncoResponse Company Profile - Craft
OncoResponse is an immuno-oncology company. The Company is engaged in providing cancer research into immunotherapies. It licensed the I-STAR™ platform, developed to interrogate …See details»
OncoResponse 2025 Company Profile: Valuation, Funding
OncoResponse General Information Description. Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of cancer patients who have …See details»
OncoResponse - Overview, News & Similar companies
OncoResponse, Inc., an immuno-oncology focused biotech company, in a broad strategic alliance with MD Anderson Cancer Center, uses a proprietary B-cell technology platform to mine the …See details»
ONCORESPONSE, INC. - CAGE.report
ONCORESPONSE, INC. Trade Name ("Doing Business As ..."): DUNS Number: 117196603 Parent DUNS Number: Address, line 1: 1124 Columbia St Ste 300 Address, line 2: ...See details»
OncoResponse - LinkedIn
OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders.See details»
Board of Directors - About - OncoResponse
John serves on the board of Allakos, Inc., Tioma Therapeutics, Inc., Viba Therapeutics, Inc. and OncoResponse, Inc., all RiverVest portfolio companies. He is a former director at Otonomy, …See details»
OncoResponse, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore OncoResponse, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 31 news, and 1 literature, Disease Domain:Neoplasms, Hemic and Lymphatic …See details»
OncoResponse Company Overview, Contact Details
OncoResponse, Inc. hired Sean A. McCarthy as Independent Director to Board of Directors on Jul 7th '21. OncoResponse, a biotechnology company harnessing the power of the human …See details»
OncoResponse Raises $40.6 Million Series C Financing
Mar 31, 2021 For more information please visit: www.oncoresponseinc.com. Investor Contact: Solebury Trout John Graziano +1 646-378-2942 jgraziano@troutgroup.com. TagsSee details»
OncoResponse, a MD Anderson Cancer Center partner, receives …
Jun 13, 2023 A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas. The nearly $13.3 million grant given to …See details»